Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Chemistry ; 26(69): 16455-16462, 2020 Dec 09.
Artigo em Inglês | MEDLINE | ID: mdl-32762122

RESUMO

Donor-acceptor interactions are ubiquitous in the design and understanding of host-guest complexes. Despite their non-covalent nature, they can readily dictate the self-assembly of complex architectures. Here, a photo-/redox-switchable metal-organic nanocapsule is presented, which was assembled by using lanthanide ions and viologen building blocks, by relying on such donor-acceptor interactions. The potential of this unique barrel-shaped structure is highlighted for the encapsulation of suitable electron donors, akin to the well-investigated "blue-box" macrocycles. The light-triggered reduction of the viologen units has been investigated by single-crystal-to-single-crystal X-ray diffraction experiments, complemented by magnetic, optical, and solid-state electrochemical characterizations. Density functional theory (DFT) calculations were employed to suggest the most likely electron donor in the light-triggered reduction of the viologen-based ligand.

2.
Bioorg Med Chem ; 22(2): 796-803, 2014 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-24365390

RESUMO

Molecular imaging is an ideal platform for non-invasive detection and assessment of cancer. In recent years, the targeted imaging of CXCR4, a chemokine receptor that has been associated with tumour metastasis, has become an area of intensive research. In our pursuit of a CXCR4-specific radiotracer, we designed and synthesised a novel derivative of the CXCR4 peptidic antagonist TN14003, CCIC16, which is amenable to radiolabelling by chelation with a range of PET and SPECT radiometals, such as (68)Ga, (64)Cu and (111)In as well as (18)F (Al(18)F). Potent in vitro binding affinity and inhibition of signalling-dependent cell migration by unlabelled CCIC16 were confirmed by a threefold uptake in CXCR4-over-expressing cells compared to their isogenic counterparts. Furthermore, in vivo experiments demonstrated the favourable pharmacokinetic properties of the (68)Ga-labelled tracer (68)Ga-CCIC16, along with its CXCR4-specific accumulation in tissues with desirable contrast (tumour-to-muscle ratio: 9.5). The specificity of our tracer was confirmed by blocking experiments. Taking into account the attractive intrinsic PET imaging properties of (68)Ga, the comprehensive preclinical evaluation presented here suggests that (68)Ga-CCIC16 is a promising PET tracer for the specific imaging of CXCR4-expressing tumours.


Assuntos
Neoplasias/diagnóstico , Peptídeos , Tomografia por Emissão de Pósitrons , Receptores CXCR4/antagonistas & inibidores , Animais , Linhagem Celular Tumoral , Feminino , Radioisótopos de Gálio , Humanos , Camundongos Endogâmicos BALB C , Peptídeos/química , Peptídeos/metabolismo , Receptores CXCR4/metabolismo , Fatores de Tempo , Distribuição Tecidual
3.
J Labelled Comp Radiopharm ; 57(2): 92-6, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24307532

RESUMO

This study reports the radiosynthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline [(18) F]5 for positron emission tomography imaging of epidermal growth factor receptor (EGFR). The tracer was obtained in 47.7 ± 7.5% (n = 3) decay-corrected radiochemical yield from 2-[(18) F]fluoro-2-deoxy-ß-d-glucopyranosyl azide, and the overall nondecay-corrected radiochemical yield from aqueous fluoride was 8.6 ± 2.3% (n = 3). An in vitro preliminary cellular uptake study showed selectivity of the tracer for EGFR-positive A431 cell lines versus EGFR-negative MCF-7 cell lines. [(18) F]5 tracer uptake in A431 cells was significantly reduced by addition of the cold isotope analogue compound 5.


Assuntos
Azidas/síntese química , Desoxiglucose/análogos & derivados , Receptores ErbB/metabolismo , Radioisótopos de Flúor/química , Quinolinas/síntese química , Compostos Radiofarmacêuticos/síntese química , Azidas/farmacologia , Desoxiglucose/síntese química , Desoxiglucose/farmacologia , Humanos , Marcação por Isótopo , Células MCF-7 , Ligação Proteica , Quinolinas/farmacologia , Compostos Radiofarmacêuticos/farmacologia
4.
J Labelled Comp Radiopharm ; 56(13): 679-85, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25196030

RESUMO

Huisgen cycloaddition is attractive to label peptide because of its rapidity and bioorthogonality. However, for larger tracers, the physico-chemical differences between the precursor and the tracer are usually insufficient to allow their separation by HPLC, reducing the specific activity. This is of importance for peptidic tracers because the combination of their high-affinity receptor with low specific activity results in the precursor saturating the receptors, causing non-specific tracer binding. Here, we report a fast, one-pot, general strategy to circumvent this issue, yielding a tracer of improved specific activity. It consists in adding a lipophilic azide after the labeling step to scavenge unreacted precursor into a more lipophilic species that does not co-elute with the tracer. We applied this strategy to a new fluorinated cyclopentapeptidic CXCR4 antagonist for the PET imaging of cancer, CCIC15, for which we managed to reduce the apparent peptide concentration by a factor of 34 in 10 min. This tracer was radiolabeled by click chemistry with 2-[(18) F]fluoroethylazide, yielding the tracer in 18 ± 6% (n = 5) end-of-synthesis radiochemical yields (EOS-RCY) in 1.5 h from [(18) F]fluoride with a specific activity of 19.4 GBq µmol(-1) . Preliminary biological evaluation of the probe confirmed potency and specificity for CXCR4; further biological evaluation is underway.


Assuntos
Peptídeos Cíclicos/química , Peptídeos Cíclicos/síntese química , Compostos Radiofarmacêuticos/síntese química , Receptores CXCR4/metabolismo , Azidas/química , Linhagem Celular Tumoral , Humanos , Peptídeos Cíclicos/farmacologia , Compostos Radiofarmacêuticos/química , Compostos Radiofarmacêuticos/farmacologia
5.
ChemMedChem ; 11(1): 38-42, 2016 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-26486566

RESUMO

Ligand efficiency has proven to be a valuable concept for optimization of leads in the early stages of drug design. Taking this one step further, group efficiency (GE) evaluates the binding efficiency of each appendage of a molecule, further fine-tuning the drug design process. Here, GE analysis is used to systematically improve the potency of inhibitors of Mycobacterium tuberculosis pantothenate synthetase, an important target in tuberculosis therapy. Binding efficiencies were found to be distributed unevenly within a lead molecule derived using a fragment-based approach. Substitution of the less efficient parts of the molecule allowed systematic development of more potent compounds. This method of dissecting and analyzing different groups within a molecule offers a rational and general way of carrying out lead optimization, with potential broad application within drug discovery.


Assuntos
Antituberculosos/farmacologia , Descoberta de Drogas/métodos , Inibidores Enzimáticos/farmacologia , Mycobacterium tuberculosis/enzimologia , Peptídeo Sintases/antagonistas & inibidores , Antituberculosos/síntese química , Antituberculosos/química , Cristalografia por Raios X , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/química , Modelos Moleculares , Estrutura Molecular , Peptídeo Sintases/metabolismo , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA